Table 3.
Population pharmacokinetic and pharmacokinetic/pharmacodynamic variables of ponesimod and its effects on total lymphocyte count
| Variables | Estimate | Interindividual variability (%) | CV (%) |
|---|---|---|---|
| Pharmacokinetic variables | |||
| ka (h−1) | 0.67 | 55.0 | 12.1 |
| Vcentral/F (l) | 304 | 14.3 | 3.4 |
| Vperipheral/F (l) | 979 | 119 | 5.6 |
| CL/F (l h−1) | 6.7 | 14.3 | 10.6 |
| CLD/F (l h−1) | 3.6 | 0.002 | 21.8 |
| Pharmacokinetic/pharmacodynamic variables | |||
| kin (%) | 45.8 | – | 10.5 |
| kout (h−1) | 0.36 | – | 9.86 |
| IC50 (ng ml−1) | 65.1 | – | 25.4 |
| Imax (%) | 94 | – | 9.85 |
Abbreviations are as follows: CL/F, apparent clearance; CLD/F, distribution clearance; CV, coefficient of variation; IC50, half-maximal inhibitory concentration; Imax, maximal inhibitory effect; ka, first-order absorption rate constant; kin, zero-order lymphocyte influx rate constant; kout, first-order lymphocyte efflux rate constant; Vcentral/F, apparent volume of central compartment; and Vperipheral/F, apparent volume of peripheral compartment.